MOG is a significant target in the study of inflammatory demyelinating diseases such as multiple sclerosis (MS) and MOG antibody-associated disease (MOGAD). The presence of MOG antibodies (Abs) has been linked to various CNS disorders, including acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders (NMOSD), and optic neuritis (ON) . These antibodies can be transient in some diseases, like ADEM, or persistent in others, such as NMOSD and recurrent ON.
Recombinant human MOG (rhMOG) is produced using genetic engineering techniques to express the MOG protein in a host system, such as bacteria. This recombinant protein is used in research to study the immune response in demyelinating diseases. One of the challenges in producing rhMOG has been its insolubility when overexpressed in bacterial cells, requiring inefficient denaturation and refolding steps .
Recent advancements have led to the development of high-yield production methods for soluble rhMOG using SHuffle cells, a commercially available E. coli strain engineered to facilitate disulfide bond formation in the cytoplasm . This method simplifies the production process and yields a well-folded, homogeneous monomeric protein that can be used in various research applications.
Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model for studying CNS autoimmune demyelinating diseases. Immunization with the extracellular domain of rhMOG, which contains pathogenic antibody and T cell epitopes, induces B cell-dependent EAE in mice . This model helps researchers understand the mechanisms of disease and test potential therapeutic interventions.
The detection of MOG Abs in patients has clinical implications for diagnosing and managing various demyelinating diseases. Improved detection methods using cell-based assays with recombinant full-length, conformationally intact MOG have revealed that MOG Abs can be found in a subset of patients with different CNS disorders . Understanding the role of MOG Abs in these diseases can help in developing targeted therapies and improving patient outcomes.